Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Ayuso JR, Ripollés T, Bouzas R, Gironella M, García-Albéniz X, Feliu J, Maurel J.
Pineda E, et al.
Tumour Biol. 2017 Jun;39(6):1010428317705509. doi: 10.1177/1010428317705509.
Tumour Biol. 2017.
PMID: 28621236
Free article.
Clinical Trial.